Abstract
INSULIN resistance and hyperinsulinism after pancreas transplantation are well known consequences due to immunosuppressive therapy and systemic insulin delivery. Impaired glycemic control may develop. The differentiation from pancreas rejection may be difficult; pancreas biopsy is still a diagnostic tool not widely used. Glucose tolerance tests provide information on the secretory function of the b cell. Fasting insulin levels are often variable and interpretation can be difficult. To assess insulin resistance in recipients of a pancreas–kidney transplant we employ the euglycemic hyperinsulinemic clamp (EHC) as developed by De Fronzo in 1979. The following case report illustrates the use of EHC to investigate the impact of immunosuppressant drugs in a patient with progressively deteriorating glycemic control within the first 6 months after transplantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
